PQ
PQ6.F Starpharma Holdings Limited
- Market cap
- EUR 120M
- P/E
- -
- P/B
- 14.14x
- ROE
- -54.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is PQ6.F undervalued?
Graham numberThe Graham number of Starpharma Holdings Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Starpharma Holdings Limited fundamental analysis
No fundamental analysis for Starpharma Holdings Limited yet.
Starpharma Holdings Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Starpharma Holdings Limited
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating.…
Full company profileStarpharma Holdings Limited financial statements
Starpharma Holdings Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 2.99M | 3.81M | 1.65M | 6.03M | 1.80M | 4.68M | 2.94M | 8.29M | 4.91M | 12.1M |
| Gross Profit | 2.99M | 3.81M | 1.40M | 5.14M | 1.01M | 1.91M | 1.82M | 7.66M | 3.69M | 11.3M |
| Operating Income | -15.9M | -11.4M | -15.3M | -15.8M | -21.4M | -17.7M | -18.2M | -10.7M | -12.0M | -8.99M |
| EBITDA | -15.2M | - | - | - | - | -16.6M | -17.0M | -9.63M | -10.9M | -8.08M |
| Net Income | 8.20M | -10.3M | -14.3M | -14.7M | -19.7M | -16.2M | -15.6M | -8.17M | -9.99M | -7.47M |
| EPS | 0.02 | -0.03 | -0.04 | -0.04 | -0.05 | -0.04 | -0.04 | -0.02 | -0.02 | -0.02 |
| Balance Sheet | ||||||||||
| Total Assets | 66.6M | 58.5M | 48.9M | 39.1M | 73.2M | 66.2M | 52.1M | 36.8M | 25.4M | 19.0M |
| Total Liabilities | 5.61M | 5.23M | 6.46M | 7.75M | 10.9M | 17.8M | 17.3M | 8.70M | 6.42M | 5.24M |
| Shareholders' Equity | 61.0M | 53.3M | 42.4M | 31.3M | 62.3M | 48.4M | 34.8M | 28.1M | 19.0M | 13.8M |
| Cash & Short-term Investments | 61.2M | 51.3M | 41.3M | 30.1M | 60.5M | 49.9M | 35.2M | 23.4M | 15.4M | 11.0M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -17.0M | -10.2M | -10.3M | -10.8M | -14.8M | -13.2M | -13.5M | - | - | - |
| Capital Expenditure | 625K | 359K | 314K | 125K | 246K | 837K | 621K | 89.0K | 42.0K | 287K |
| Free Cash Flow | -17.6M | -10.6M | -10.7M | -10.9M | -15.1M | -14.0M | -14.2M | -7.07M | -6.80M | -3.50M |
| Ratios | ||||||||||
| ROE | 13.4% | -19.3% | -33.6% | -46.9% | -31.7% | -33.4% | -44.9% | -29.0% | -52.6% | -54.2% |
| ROA | 12.3% | -17.6% | -29.2% | -37.6% | -26.9% | -24.4% | -30.0% | -22.2% | -39.3% | -39.3% |
| Net Profit Margin | 274.1% | -269.8% | -863.4% | -243.3% | -1,097.4% | -345.0% | -532.1% | -98.5% | -203.4% | -62.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Starpharma Holdings Limited dividends
Starpharma Holdings Limited has not paid dividends in the last 10 fiscal years.
Who owns Starpharma Holdings Limited
- Insiders 36.00%
- Institutions 16.80%
- Public & others 47.20%
- Shares outstanding 483M
- Free float 329M
Starpharma Holdings Limited company profile
- Company name
- Starpharma Holdings Limited
- Ticker
- PQ6.F
- ISIN
- AU000000SPL0
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 50
- Fiscal year end
- June
- Address
- Suite 3.02, Richmond, VIC, Australia, 3121
- Phone
- 61 3 8532 2700
- Website
- starpharma.com
About Starpharma Holdings Limited
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It also involved in the development of a dendrimer-enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial. In addition, the company is developing DEP HER2 radiodiagnostic and DEP HER2 ADC to treat solid tumors; DEP technology for antibody-drug conjugates; and SPL7013 for vaginal gel, a treatment of bacterial vaginosis and prevention of recurrent BV, and an antiviral condom. It has a collaboration agreement with Medicxi to develop petalion therapeutics, a novel cancer therapy using Starpharma's dendrimer technology. Starpharma Holdings Limited was incorporated in 1997 and is based in Richmond, Australia.
Starpharma Holdings Limited management
4- Ms. Cheryl Maley B.Sc., M.B.A.CEO, MD & Director · born 1969
- Mr. Justin CahillChief Financial and Operations Officer & Company Secretary
- Ms. Sindy SmithCommunications & Investor Relations Manager
- Ms. Miranda SowdenDirector of People & Culture